Cambridge Healthtech Institute’s 18th Annual

Target Identification and Validation

Part 1: Proteomics-Based Target Discovery

September 28-29, 2021

Part 2: Genomics-Based Target Discovery

September 29-30, 2021

 

Finding novel, druggable targets for therapeutic intervention remains a top priority for the pharma/biotech industry. However, identifying and validating "good" targets remains a formidable challenge. Genomics and proteomics tools have continued to be exploited in target discovery but how well are they working? How are innovations in artificial intelligence, metabolomics and other areas contributing to target discovery? What’s being done to adequately validate the targets once they are identified? What strategies are being employed to go after difficult or “undruggable” targets? Cambridge Healthtech Institute’s conference on Target Identification and Validation will bring together leading experts from around the world to discuss some of these critical issues and to share ideas and best practices.

 

Who should attend: Scientists in Molecular and Cellular Biology, Discovery Biology, Target Discovery, Target Identification and Validation, Chemical Biology, Proteomics, Genetics, Systems Biology, Assay Development, High Throughput Screening, Molecular Screening, Discovery Informatics, and Computational Biology

 

Part 1:

Besides target identification, target deconvolution and validation remain important bottlenecks in drug discovery. Proteomics, particularly chemical biology and mass spectrometry (MS)-based tools and assays are playing an important role in identifying, evaluating and priortizing new drug targets. The first part of the Target Identification and Validation conference focuses on proteomics-based target discovery that leverages these new chemical probes, assays and screening tools being developed.

 

Coverage will include, but is not limited to:

 

  • New methodologies for target deconvolution and validation using small molecules and peptides
  • Applications of chemoproteomic strategies: MS, affinity assays, thermal profiling, activity-based protein profiling
  • Design and use of new chemical probes and assays for proteomics-based target discovery
  • Biophysical and cellular assays for studying target binding and engagement
  • Phenotypic versus target-based screening approaches
  • Chemical proteomics for emerging drug targets- transcription factors, epigenetic readers, RNA, transporters

 

Part 2:

The second part of the Target Identification and Validation conference focuses on genomics-based target discovery. It includes applications of CRISPR, chemical genetics, single cell sequencing, spatial genomics and other genomics-based tools to identify and validate new drug targets. Complementary use of these genomics technologies with AI/machine learning, imaging and other approaches will be discussed.

 

Coverage will include, but is not limited to:

 

  • Use of CRISPR, CRISPRi/a, and chemical genomic screens for finding novel targets
  • Functional genomics approaches for in vitro and in vivo target screening
  • Use of whole genome sequencing, single cell sequencing, spatial genomics for target screening
  • Using data mining and visualization tools to identify, evaluate and prioritize drug targets
  • Exploring AI/ML tools and pathway analysis for associating targets and diseases
  • Case studies on how to deconvolute and prioritize druggable targets from screening hits      

 

If you would like to submit a proposal to give a presentation at this meeting, please click here.

 

The deadline for priority consideration is March 29, 2021.

 

All proposals are subject to review by session chairpersons and/or the Scientific Advisory Committee to ensure the overall quality of the conference program. Additionally, as per Cambridge Healthtech Institute policy, a select number of vendors and consultants who provide products and services will be offered opportunities for podium presentation slots based on a variety of Corporate Sponsorships.

 

For more details on the conference, please contact:

Tanuja Koppal, PhD

Senior Conference Director

Cambridge Healthtech Institute

Email: tkoppal@healthtech.com

 

For partnering and sponsorship information, please contact:

Rod Eymael

Manager, Business Development

Cambridge Healthtech Institute

Phone: (+1) 781-247-6286

Email: reymael@healthtech.com


Please click here to return to the agenda for Target Identification and Validation - Part 1


Submit a Speaker Proposal